Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19

Current formulations and dose regimens of hydroxychloroquine (HCQ) put patients at risk of harm. An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Further, almost all of the trials reg...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Med Hypotheses
Main Authors: Kavanagh, Oisín, Marie Healy, Anne, Dayton, Francis, Robinson, Shane, O'Reilly, Niall J., Mahoney, Brian, Arthur, Aisling, Walker, Gavin, Farragher, John P.
Format: Artigo
Jezik:Inglês
Izdano: Elsevier Ltd. 2020
Teme:
Letter to Editors
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7361049/
https://ncbi.nlm.nih.gov/pubmed/33017904
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.mehy.2020.110110
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki